Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.
Scientists may be learning why it’s so hard to stop the cycle of violence. The answer may lie in the nervous system.
One in five Americans have allergic rhinitis, a number that is steadily rising, but the exact reasons for this increase are unknown. A new lipid-based nasal ointment is found effective at reducing symptoms of allergic rhinitis in German patients.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice to consumers and the herbal sector about the poor quality of some traditional chinese medicines (TCMs) on the UK market.
AstraZeneca has announced that the U.S. Food and Drug Administration has approved revised labeling for its anti-inflammatory corticosteroid nasal spray RHINOCORT AQUA® (budesonide).
Childhood nephrotic syndrome, which affects 3 out of 100,000 children, is the most common chronic kidney disease in children. Although it does not impair kidney function, it weakens the body's ability to remove water and salt from the blood, and causes swelling in the belly, legs, and around the eyes.
Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.
A study presented today at the 100th International Conference of the American Thoracic Society in Orlando shows pediatric asthma patients given a certain inhaled corticosteroid had a 29 percent lower risk of ending up in the emergency department (ED) or being admitted into the hospital.
A new guideline developed by the American Academy of Neurology and the Child Neurology Society evaluates the treatment of infantile spasms. The guideline is published in the May 25 issue of Neurology, the scientific journal of the American Academy of Neurology.
New data presented at the American Thoracic Society’s 2004 International Conference show that once-daily treatment with the investigational therapy Alvesco (ciclesonide) in mild-to-moderate asthma patients has no effect on normal adrenal function, as demonstrated by measurements of the hypothalamic-pituitary-adrenal (HPA)-axis.
Connetics Corporation, a specialty pharmaceutical company that develops and commercializes dermatology products, announced today that on May 4, 2004 the United States Patent and Trademark Office (USPTO) issued to Connetics Patent No. 6,730,288 B1. The patent has 7 independent product claims, and covers a pharmaceutical aerosol foam composition having occlusive capability.
Most toddlers and preschoolers will be diagnosed with fluid in their middle ears--or otitis media with effusion (OME)--at some time before school age.
The National Psoriasis Foundation, Dermatology Nurses Association, Dermatologists and People with Psoriasis have collaborated to offer a new resource to help people with psoriasis cope with the social and emotional impact of psoriasis.
Atrix Laboratories, Inc. announced today the company received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for fluticasone propionate cream, 0.05%.
A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.
SkyePharma PLC has announced that its proprietary delivery technologies for respiratory drugs will be presented later this month at two international conferences, one in the UK and one in America.
GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) approved the use of Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone.
ALTANA AG has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted ALTANA Pharma marketing approval for Alvesco (Ciclesonide)
When patients with life-threatening bacterial infections are allergic to antibiotics, drug desensitization may be an option when no other alternative exists according to a report published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
GlaxoSmithKline plc announced today that it has filed SeretideTM DiskusTM for approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of asthma in adults and children.
Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the drug-treated diabetic retinopathy population will quadruple by 2012.